Abstract Body

Background: The HIV-1 protease is crucial to the maturation of budding virions. Low adherence to protease inhibitors due to toxicity cause both primary active site mutations, which result in a loss of enzymatic fitness, and accessory mutations, which restore fitness and stability of the enzyme, to arise. The contribution of accessory mutations in conferring drug resistance has been studied in great detail but remains elusive. Discerning the synergy of both types of mutations to sustain resistance to highly potent inhibitors while perpetuating viral longevity is the basis of this study. Kinetic and structural analyses of four accessory mutations have revealed possible interdependent mechanisms of mutations beyond the active site and their role in drug resistance. Methodology: In this study, four HIV-1 protease mutants, L76V, L90M, V32I, and V32I+L33F, were characterized for their impact on Darunavir inhibition. Each of the mutants was first tested for DRV susceptibility using a FRET based kinetics assay that measures the fluorescence intensity readout of a hydrolyzed Matrix-Capsid substrate mimic. Each of the four mutants were then co-crystallized with DRV and characterized for changes in static Cα distances, hydrogen bonding, and van der Waals contacts. Using the trajectories from 10ns molecular dynamics simulations the root mean square deviations and fluctuations for each mutant complex was assessed. The trajectories from the simulations were also used to calculate distances for inter and intra- monomeric active site residue pairs to determine the bearing of accessory mutations on active site residues. Results: Although the four mutations observed in this study do not directly lie within the active site or bind to DRV they each impact various aspects of DRV inhibition including a 22.5 fold change in KI exhibited by the V32I+L33F double mutant. Analyses of the co-crystal structures reveal that while no major changes can be observed in both overall structure and static Cα distances, there are significant changes in van der Waals contacts upon the introduction of L33F. Results from molecular dynamics simulations suggest that each mutation affects DRV binding via a network of intra-monomeric main chain polar contacts to reduce protease susceptibility to DRV by altering the conformations of residues within the active site. Conclusions: The interdependent mechanisms of resistance employed by the accessory mutations in this study account for loss of susceptibility to one of the most potent HIV-1 protease inhibitors. Detailed structural analyses employing similar methodologies described above could potentially lead to further discernment of the synergy of accessory mutations and aid in proactively meliorating the current HIV-1 protease inhibitor armamentarium.